GSK Investigational Site

Fitzroy North, Victoria 3078

0 studies enrolling now · 3 studies all time

What they study most

HIV Infections, Infection, Human Immunodeficiency Virus, Infection, Human Immunodeficiency Virus I

Studies at this site

• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) — Completed
• Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) — Completed
• A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) — Completed